Interaction between Burkholderia pseudomallei and the host immune response: Sleeping with the enemy?

Journal of Infectious Diseases

Volumn 192, Issue 10, 2005, Pages 1845-1850

  Gan, Yunn Hwen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ARTICLE; AUSTRALIA; BACTERIAL VIRULENCE; BIOLOGICAL WARFARE; BURKHOLDERIA PSEUDOMALLEI; CHRONIC DISEASE; CLINICAL FEATURE; DISEASE COURSE; ENDEMIC DISEASE; HUMAN; IMMUNE RESPONSE; INFECTION SENSITIVITY; MELIOIDOSIS; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; SOUTHEAST ASIA; WESTERN HEMISPHERE;

ANIMALS; BURKHOLDERIA PSEUDOMALLEI; CRICETINAE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, NATURAL; MELIOIDOSIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RATS; VIRULENCE;

EID: 27744551052     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/497382     Document Type: Article

References (51)

1. Dance DA. Melioidosis: the tip of the iceberg? Clin Microbiol Rev 1991; 4:52-60.
2. Holden MTG, Titball RW, Peacock SJ, et al. Genoraic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci USA 2004; 101:14240-5.
3. White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; 2:697-701.
4. Leelarasamee A. Recent development in melioidosis. Curr Opin Infect Dis 2004; 17:131-6.
5. Chaowagul W, White NJ, Dance DA, et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 1989; 159:890-9.
6. Koponen MA, Zlock D, Palmer DL, Merlin TL. Melioidosis, but not gone! Arch Intern Med 1991; 151:605-8.
7. Mays EE, Ricketts EA. Melioidosis: recrudescence associated with bronchogenic carcinoma twenty-six years following initial geographic exposure. Chest 1975; 68:261-3.
8. Ngauy V, Lemeshev Y, Sadkowski L, Crawford G. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol 2005; 43:970-2.
9. Janeway CA Jr, Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 1998; 10: 349-50.
10. Kawahara K, Dejsirilert S, Danbara H, Ezaki T. Extraction and characterization of lipopolysaccharide from Pseudomonas pseudomallei. FEMS Microbiol Lett 1992; 75:129-33.
11. Matsuura M, Kawahara K, Ezaki T, Nakano M. Biological activities of lipopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. FEMS Microbiol Lett 1996; 137:79-83.
12. Utaisincharoen P, Tangthawornchaikul N, Kespichayawattna W, Anuntagool N, Chaisuriya P, Sirisinha S. Kinetic studies of the production of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) in macrophages stimulated with Burkholderia pseudomallei endotoxin. Clin Exp Immunol 2000; 122:324-9.
13. Portnoy DA. Manipulation of innate immunity by bacterial pathogens. Curr Opin Immunol 2005; 17:25-8.
14. Kawasaki K, Ernst RK, Gowen BB, Miller SI, Hinnebusch BJ. 3-O-deacylation of lipid A by PagL, a PhoP/PhoQ-regulated deacylase of Salmonella typhimurium, modulates signaling through Toll-like receptor 4. J Biol Chem 2004; 279:20044-8.
15. Daveau RP, Pham TT, Lemley K, et al. Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both Toll-like receptors 2 and 4. Infect Immun 2004; 72:5041-51.
16. Utaisincharoen P, Tangthawornchaikul N, Kespichayawattana W, Chaisuriya P, Sirisinha S. Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) production: a possible mechanism of evading macrophage killing. Microbiol Immunol 2001; 45:307-13.
17. Utaisincharoen P, Anuntagool N, Arjcharoen S, et al. Burkholderia pseudomallei stimulates low interleukin-8 production in the human lung epithelial cell line A549. Clin Exp Immunol 2004; 138:61-5.
18. Reckseidler-Zenteno SL, DeVinney R, Woods DE. The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect Immun 2005; 73:1106-15.
19. Jones AL, Beveridge TJ, Woods DE. Intracellular survival of Burkholderia pseudomallei. Infect Immun 1996; 64:782-90.
20. Stevens MP, Wood MW, Taylor LA, et al. An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol Microbiol 2002;46:649-59.
21. Kespichayawattana W, Rattanachetkul S, Wanun T, Utaisincharoen P, Sirisinha S. Burkholderia pseudomallei induces cell fusion and actin-associated membrane protrusion: a possible mechanism for cell-to-cell spreading. Infect Immun 2000; 68:5377-84.
22. Breitbach K, Rottner K, Klocke S, et al. Actin-based motility of Burkholderia pseudomallei involves the Arp 2/3 complex, but not N-WASP and Ena/VASP proteins. Cell Microbiol 2003; 5:385-93.
23. Stevens MP, Friebel A, Taylor LA, et al. A Burkholderia pseudomallei type III secreted protein, BopE, facilitates bacterial invasion of epithelial cells and exhibits guanine nudeotide exchange factor activity. J Bacteriol 2003; 185:4992-6.
24. Sun GW, Lu J, Pervaiz S, Cao WP, Can YH. Caspase-1 dependent macrophage death induced by Burkholderia pseudomallei. Cell Microbiol 2005; 7:1447-58.
25. Gaillard JL, Berche P, Mounier J, Richard S, Sansonetti P. In vitro model of penetration and intracellular growth of Listeria monocytogenes in the human enterocyte-like cell line Caco-2. Infect Immun 1987; 55:2822-9.
26. Bielecki J, Youngman P, Connelly P, Portnoy DA. Bacillus subtilis expressing a haemolysin gene from Listeria mtmacytogenes can grow in mammalian cells. Nature 1990; 345:175-6.
27. Dye C, Scheele S, Dolin R, Pathania G, Raviglione M. Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country. JAMA 1999; 282:677-86.
28. Boshoff HI, Barry CE. Tuberculosis-metabolism and respiration in the absence of growth. Nat Rev Microbiol 2005; 3:70-80.
29. Lillebaek T, Dirksen A, Vynnycky E, Baess I, Thomsen VO, Andersen AB. Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J Infect Dis 2003; 188:1032-9.
30. Seiler P, Ulrichs T, Bandermann S, et al. Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. J Infect Dis 2003; 188:1326-31.
31. Flynn JL, Chan J. Tuberculosis: latency and reactivation. Infect Immun 2001; 69:4195-201.
32. Reechaipichitkul W. Clinical manifestation of pulmonary melioidosis in adults. Southeast Asian J Trop Med Public Health 2004; 35:664-9.
33. Wuthiekanun V, Smith MD, White NJ. Survival of Burkholderia pseudomallei in the absence of nutrients. Trans R Soc Trop Med Hyg 1995; 89:491.
34. Chen K, Sun GW, Chua KL, Gan YH. Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments. Antimicrob Agents Chemother 2005; 49:1002-9.
35. Rosenberger CM, Finlay BB. Macrophages inhibit Salmonella typhimurium replication through MEK/ERK kinase and phagocyte NADPH oxidase activities. J Biol Chem 2002; 277:18753-62.
36. Brett PJ, Mah DCW, Woods D. Isolation and characterization of Pseudomonas pseudomallei flagellin proteins. Infect Immun 1994; 62:1914-9.
37. DeShazer D, Brett PJ, Carlyon R, Woods DE. Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene. J Bacteriol 1997; 179:2116-25.
38. Leakey AK, Ulett GC, Hirst RG. BALB/c and C57B1/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb Pathog 1998; 24:269-75.
39. Hoppe I, Brenneke B, Rohde M, et al. Characterization of a murine model of melioidosis: comparison of different strains of mice. Infect Immun 1999; 67:2891-900.
40. Liu B, Koo GC, Yap EH, Chua KL, Can YH. Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infect Immun 2002; 70:504-11.
41. Ulett GC, Ketheesan N, Hirst RG. Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei. Infect Immun 2000; 68:2034-42.
42. Santanirand P, Harley VS, Dance DA, Drasar BS, Bancroft GJ. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect Immun 1999; 67:3593-600.
43. Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ. Bystander activation of CD8+ T cells contributes to the rapid production of IFNγ in response to bacterial pathogens. J Immunol 2001; 166:1097-105.
44. Barnes JL, Ulett GC, Ketheesan N, Clair T, Summers PM, Hirst RG. Induction of multiple chemokine and colony-stimulating factor genes in experimental Burkholderia pseudomallei infection. Immunol Cell Biol 2001; 79:490-501.
45. Lauw FN, Simpson AJH, Prins JM, et al. Elevated plasma concentrations of interferon-γ (IFN-γ) and the IFN-γ-inducing cytokines interleukin (IL)-IS, IL-12 and IL-15 in severe melioidosis. J Infect Dis 1999; 180:1878-85.
46. Ketheesan N, Barnes JL, Ulett GC, et al. Demonstration of a cell-mediated immune response in melioidosis. J Infect Dis 2002; 186:286-9.
47. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26:510-3.
48. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology and management. Clin Microbiol Rev 2005; 18:383-416.
49. Geerlings SE, Hoepelman AIM. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26:259-65.
50. Graves DT, Naguib G, Lu H, Leone C, Hsue H, Krall E. Inflammation is more persistent in type I diabetic mice. J Dent Res 2005; 84:324-8.
51. O'Connor JC, Satpathy A, Hartman ME, et al. IL-1β-mediated innate immunity is amplified in the db/db mouse model of type 2 diabetes. J Immunol 2005; 174:4991-7.